These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28702814)

  • 21. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low.
    Li J; Chung S; Wei EK; Luft HS
    BMC Health Serv Res; 2018 Jul; 18(1):525. PubMed ID: 29976189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of risk prediction models to lung cancer screening: a review.
    Tammemägi MC
    J Thorac Imaging; 2015 Mar; 30(2):88-100. PubMed ID: 25692785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial.
    Becker N; Motsch E; Trotter A; Heussel CP; Dienemann H; Schnabel PA; Kauczor HU; Maldonado SG; Miller AB; Kaaks R; Delorme S
    Int J Cancer; 2020 Mar; 146(6):1503-1513. PubMed ID: 31162856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the impact of novel systemic treatments on lung cancer screening benefits.
    Gogebakan KC; Lange J; Slatore CG; Etzioni R
    Cancer; 2023 Jan; 129(2):226-234. PubMed ID: 36320180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Tammemägi MC; Cina K; Kitts AKB; Koop D; Petereit MA; Sargent M; Petereit DG
    Cancer; 2023 Dec; 129(24):3894-3904. PubMed ID: 37807694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force.
    Meza R; Cao P; Jeon J; Taylor KL; Mandelblatt JS; Feuer EJ; Lowy DR
    J Thorac Oncol; 2022 Jan; 17(1):160-166. PubMed ID: 34648947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute.
    Gohagan J; Marcus P; Fagerstrom R; Pinsky P; Kramer B; Prorok P;
    Chest; 2004 Jul; 126(1):114-21. PubMed ID: 15249451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Schreuder A; Mets OM; Schaefer-Prokop CM; Jacobs C; Prokop M
    Lung Cancer; 2021 Jun; 156():5-11. PubMed ID: 33866117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence to annual lung cancer screening with low-dose CT scan in a diverse population.
    Erkmen CP; Dako F; Moore R; Dass C; Weiner MG; Kaiser LR; Ma GX
    Cancer Causes Control; 2021 Mar; 32(3):291-298. PubMed ID: 33394208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Landy R; Cheung LC; Young CD; Chaturvedi AK; Katki HA
    Cancer; 2024 Jan; 130(2):201-215. PubMed ID: 37909885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Life-Gained-Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening.
    Cheung LC; Berg CD; Castle PE; Katki HA; Chaturvedi AK
    Ann Intern Med; 2019 Nov; 171(9):623-632. PubMed ID: 31634914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of Risk Factor-Based Guidelines and Model-Based Chest CT Lung Cancer Screening in World Trade Center-Exposed Fire Department Rescue/Recovery Workers.
    Cleven KL; Vaeth B; Zeig-Owens R; Colbeth HL; Jaber N; Schwartz T; Weiden MD; Markowitz SB; Silvestri GA; Prezant DJ
    Chest; 2021 May; 159(5):2060-2071. PubMed ID: 33279511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
    Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
    Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    Taksler GB; Peterse EFP; Willems I; Ten Haaf K; Jansen EEL; de Kok IMCM; van Ravesteyn NT; de Koning HJ; Lansdorp-Vogelaar I
    JAMA Oncol; 2021 Jun; 7(6):885-894. PubMed ID: 33914025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for Lung Cancer With Low-Dose Computed Tomography: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center.
    Smetana GW; Boiselle PM; Schwartzstein RM
    Ann Intern Med; 2015 Apr; 162(8):577-82. PubMed ID: 25894026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
    Toumazis I; Cao P; de Nijs K; Bastani M; Munshi V; Hemmati M; Ten Haaf K; Jeon J; Tammemägi M; Gazelle GS; Feuer EJ; Kong CY; Meza R; de Koning HJ; Plevritis SK; Han SS
    Ann Intern Med; 2023 Mar; 176(3):320-332. PubMed ID: 36745885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Annual number of lung cancer deaths potentially avertable by screening in the United States.
    Ma J; Ward EM; Smith R; Jemal A
    Cancer; 2013 Apr; 119(7):1381-5. PubMed ID: 23440730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.